Schering-Plough Announces Sponsorship of Rabies-Control Projects in India

Program Focus: Community Education and Mass Vaccination of Dogs in 10 Villages

KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation
(NYSE: SGP) today announced it has initiated sponsorship of two projects in
India to reduce the incidence of human and animal rabies through improved
educational awareness and mass vaccination of dogs. The company will donate
$200,000 and rabies vaccine from Intervet/Schering-Plough as well as share
expertise with partners to support successful implementation of the projects
in ten villages surrounding Bangalore and Pune, India.

"Our company has a commitment to reducing the prevalence of rabies in
vulnerable places around the world, and these new initiatives in India
demonstrate continuing support of eradication efforts," said Schering-Plough
Chairman and CEO Fred Hassan. "As with the Afya Serengeti project that
Schering-Plough supports in Africa, educating people about rabies and how to
prevent it is the most effective weapon against the disease."

Using the "Adopt a Village" concept, education about rabies prevention and
treatment will be aimed at the entire community and adapted for everyone from
small children to adults and village leaders. With guidance from the nonprofit
Global Alliance for Rabies Control, the programs will involve medical and
veterinary professors, experts in the field of rabies along with medical
students from area universities. Special accommodations will be made to
educate people in their own dialects, with sensitivity to their customs.

"Our goal is to provide a sustainable solution for communities in developing
countries to prevent rabies that takes into account how people interact with
community dogs and other animals in their environment," said Deborah J. Briggs
Ph.D., executive director, Global Alliance for Rabies Control. "Rabies remains
a neglected disease of the poor and disenfranchised, and we believe projects
such as these being developed in India will serve as models that can be
replicated in other vulnerable areas. The grim truth is that every day more
than 150 people die of rabies. More than 100 of them are children and every
one of the deaths should have been prevented."

Separate but similar projects will be implemented in two geographic areas of
India. The Global Alliance for Rabies Control will supervise projects in four
selected villages outside the city of Bangalore: Ramohally, Hulluvenahally,
Chandrappa circle and Prasanachari palya. The Alliance will partner with a
number of India-based groups to ensure maximum impact. Partners from India
include the Rabies in Asia Foundation; the National Institute of Mental Health
and Neurosciences (NIMHANS); Kempegowda Institute of Medical Sciences (KIMS)
and the Veterinary College, Bangalore. The Alliance will also develop
educational materials for teaching children worldwide about rabies prevention.

The Bombay Veterinary College, Mumbai, will take the lead role for projects in
six major villages in Pune district, namely Narayangaon, Khodad, Arvi
Pimpalgaon, Yedgaon, Alephata and Vadgaon Anand. The college will be supported
by K.N.P. College of Veterinary Science, Shirval, and Karuna Animal Health
Foundation, Narayangaon. Intervet India, the Intervet/Schering-Plough Animal
Health business located in the Pune region, will be contributing technical
support for the project as an extension of its current rabies prevention
efforts.

Rural Indian villages are especially vulnerable to rabies, according to the
World Health Organization (WHO). India reports the highest incidence of human
rabies accounting for an estimated 20,000 of the 55,000 deaths reported
worldwide each year. Three-quarters of the deaths in India occur in rural
areas with the highest rates among the poor, particularly children under the
age of 15.

The new programs in India will start with surveys to learn how well rabies
prevention is understood in the selected villages and to assess the status of
rabies among the villages' dog and other animal populations. Researchers will
also track the numbers of reported cases and human and animal deaths due to
the disease. The next phase of the program will involve massive campaigns of
public education, focusing on effective rabies prevention practices for humans
and animals as well as appropriate treatment after exposure to the disease.

Education is urgently needed because WHO research shows most deaths occur when
people bitten by, or exposed to, a rabid animal do not seek or receive
appropriate treatment. In most countries where canine rabies is prevalent,
victims of dog bites lack understanding of the importance of seeking
appropriate medical treatment from a qualified health facility. Proper wound
cleansing and immunizations, done as soon as possible after contact with a
suspect animal, can prevent the onset of rabies in virtually 100 percent of
exposures, the WHO has found. If left untreated, the fatality rate after
rabies infection is 100 percent.

The education campaigns will draw attention to the importance of vaccinating
community dogs. Improving community understanding of the life-saving value of
administering canine vaccines is crucial; the WHO has determined that the most
cost-effective strategy for preventing rabies in people is to eliminate rabies
in dogs through animal vaccinations. This will especially benefit children,
who typically have closer contact with dogs than adults and are less inclined
to report injuries sustained from playing or other interaction with the
animals.

The final phase of the Indian projects will involve a comprehensive evaluation
of whether the education and vaccination efforts produced measurable
improvements in the incidence of rabies in people, dogs and other animals.

About Schering-Plough
Schering-Plough is an innovation-driven, science-centered global health care
company. Through its own biopharmaceutical research and collaborations with
partners, Schering-Plough creates therapies that help save and improve lives
around the world. The company applies its research-and-development platform to
human prescription, animal health and consumer health care products.
Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors,
patients, customers and other stakeholders served by its colleagues around the
world. The company is based in Kenilworth, N.J., and its Web site is
www.schering-plough.com.

Intervet/Schering-Plough Animal Health is a leader in research and dedicated
to the development, production and marketing of innovative, high-quality
animal-health products for all major farm and companion animal species. For
more information about Intervet/Schering-Plough Animal Health visit:
www.intervet.com and www.intervetusa.com.

About the Global Alliance for Rabies Control

The Global Alliance for Rabies Control is the foremost non-profit organization
dedicated to eliminating rabies throughout the world. The mission of the
Alliance is to promote rabies awareness and control. The organization
contributes to support rabies control programs and educational initiatives.

The Global Alliance for Rabies and Control was established to bring together
public and private expertise in the field of rabies, including medical,
veterinary, wildlife and animal welfare agencies, to utilize a 'one medicine'
approach to establish rabies prevention programs. The Alliance coordinates the
World Rabies Day campaign and works alongside its partner institutions and
organizations. (www.rabiescontrol.net)

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release
includes certain "forward-looking statements" within the meaning of the
private Securities Litigation Reform Act of 1995, including statements related
to expectations or forecasts of future events. Schering-Plough does not assume
the obligation to update any forward-looking statement. Many factors could
cause actual results to differ materially from Schering-Plough's
forward-looking statements, including market forces, economic factors, product
availability, patent and other intellectual property protection, current and
future branded, generic or over-the-counter competition, the regulatory
process, and any developments following regulatory approval, among other
uncertainties. For further details about these and other factors that may
impact the forward-looking statements, see Schering-Plough's Securities and
Exchange Commission filings, including Part II, Item 1A "Risk Factors" in the
Company's third Quarter 2009 10-Q, filed October 29, 2009.

SOURCE Schering-Plough Corporation

Media, Fred Malley, +1-908-298-7428, or Paul Geurts, +31-485-587893; or
Investor Contacts, Janet M. Barth, or Joe Romanelli, +1-908-298-7436